<DOC>
	<DOCNO>NCT01197469</DOCNO>
	<brief_summary>The investigator hypothesise phosphodiesterase 5A inhibitor improve exercise capacity Chronic Obstructive Pulmonary Disease secondary pulmonary hypertension .</brief_summary>
	<brief_title>Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Pulmonary Hypertension ?</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>COPD Forced expiratory volume 1 second ( FEV1 ) &lt; 80 % ( FEV1/FVC &lt; 0.70 ) Right ventricular systolic pressure ( RVSP ) &gt; 30 mmHg Pulmonary Acceleration time &lt; 120 m Pulmonary stenosis echo leave ventricular outflow tract obstruction Left ventricular ejection fraction &lt; 45 % Patients take nitrate , nicorandil doxazosin . Drug contraindication : Systolic Blood Pressure &lt; 90 mmHg recent stroke unstable angina past history non arteritic anterior ischaemic optic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Secondary Pulmonary Hypertension</keyword>
</DOC>